Denmark· DK-28106468820
Breyanzi
A lisocabtagene maraleucel product, registered in Denmark by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 12 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Lisocabtagene maraleucel is registered in 12 of 19 countries.
Countries holding a registration under ATC L01XL08 (lisocabtagene maraleucel), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Lisocabtagene maraleucel · ATC L01XL08
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
Danish Medicines Agency (Denmark)- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Denmark (DK)
- ATC code
- L01XL08
- ATC class
- Lisocabtagene maraleucel
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106468820
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
37 interactions on record for lisocabtagene maraleucel.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lisocabtagene maraleucel · interactions on record
37 records
- 21 severe
- 16 moderate
Most severe, free to view
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- NatalizumabL04AA23severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01XL08
Lisocabtagene maraleucel, as other registers publish it.
- NorwayBreyanziBristol-Myers Squibb Pharma EEIG
- BelgiumBreyanziBristol-Myers Squibb Pharma
- PolandBreyanziBristol-Myers Squibb Pharma EEIG
- FinlandBreyanziBristol-Myers Squibb Pharma EEIG
- IcelandBreyanziBristol-Myers Squibb Pharma EEIG*
- CanadaBREYANZIBRISTOL-MYERS SQUIBB CANADA
- CzechiaBREYANZIBristol-Myers Squibb Pharma EEIG, Dublin
- NetherlandsBreyanzi >= 5.1 x 10^6 cellen [CD4 component], suspensie voor injectieCelgene Europe B.V.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d880f351-255f-4d91-bfd6-55bc2c2190e8 GET /v1/drugs/d880f351-255f-4d91-bfd6-55bc2c2190e8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "infusionsvæske, dispersion",
"source": "dkma",
"strength": "2915",
"auth_role": "MOD",
"dk_drugid": "28106468820",
"substance": null,
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "44655"
}See everything about lisocabtagene maraleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.